

# ForPatients

*by Roche*

Non-Small Cell Lung Cancer (NSCLC)

## **An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib**

**Trial Status**

Active, not recruiting

**Trial Runs In**

24 Countries

**Trial Identifier**

NCT04764188 MO42122

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.

**Hoffmann-La Roche**

Sponsor

**N/A**

Phase

---

**NCT04764188 MO42122**

Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**

All

**Age**

>=18 Years

**Healthy Volunteers**

No

---